Literature DB >> 22618129

Corneal changes in ectrodactyly-ectodermal dysplasia-cleft lip and palate syndrome: case series and literature review.

Anthony F Felipe1, Azin Abazari, Kristin M Hammersmith, Christopher J Rapuano, Parveen K Nagra, Baltasar Moratal Peiro.   

Abstract

The aim of this study is to describe the corneal changes in three unrelated patients with ectrodactyly-ectodermal dysplasia-cleft lip and palate (EEC) syndrome and review the literature on the possible etiology and clinical presentation of similar cases. Case 1 is an 18-year-old female with cleft lip and palate, syndactyly, and bilateral corneal pannus superiorly and inferiorly. She was initially diagnosed and treated as herpes simplex virus keratitis. Case 2 is a 3-year-old female born with cleft lip and palate, absent radial digits in both hands, and bilateral lacrimal stenosis. She developed progressive stromal scarring and neovascularization in both eyes. Her cornea perforated after developing infectious ulceration. Case 3 is a 49-year-old male with cleft palate, claw-hand deformities, absent meibomian glands and lacrimal duct, right ankyloblepharon, and a superior wedge-shaped opacity in the left cornea. The clinical findings demonstrated the different spectrum of keratopathy seen in patients with EEC. All patients were treated medically and without any surgical intervention. Limbal stem cell deficiency (LSCD) is presumed to be the cause in all three cases. Corneal changes in EEC can have variable presentation. LSCD seems to be the etiology of such keratopathy. Recurrent infection from lacrimal drainage obstruction and tear film instability are other risk factors for disease severity and progression.

Entities:  

Mesh:

Year:  2012        PMID: 22618129     DOI: 10.1007/s10792-012-9585-6

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  13 in total

Review 1.  Ocular cicatricial pemphigoid: a review of clinical features, immunopathology, differential diagnosis, and current management.

Authors:  Maria Kirzhner; Frederick A Jakobiec
Journal:  Semin Ophthalmol       Date:  2011 Jul-Sep       Impact factor: 1.975

2.  The EEC syndrome and its ocular manifestations.

Authors:  A A McNab; M J Potts; R A Welham
Journal:  Br J Ophthalmol       Date:  1989-04       Impact factor: 4.638

3.  Ocular manifestations of the ectrodactyly, ectodermal dysplasia, cleft lip-palate syndrome.

Authors:  J L Baum; M J Bull
Journal:  Am J Ophthalmol       Date:  1974-08       Impact factor: 5.258

4.  Ectrodactyly, ectodermal dysplasia, and clefting syndrome.

Authors:  M Kaiser-Kupfer
Journal:  Am J Ophthalmol       Date:  1973-12       Impact factor: 5.258

5.  Association of ectrodactyly, ectodermal dysplasia, and cleft lip-palate.

Authors:  R A Rüdiger; W Haase; E Passarge
Journal:  Am J Dis Child       Date:  1970-08

6.  Two families with dyshidrotic ectodermal dysplasia associated with ingrowth of corneal vessels, limbal hair growth, and Bitôt-like conjunctival anomalies.

Authors:  N T Tijmes; M J Zaal; P T De Jong; H J Völker-Dieben
Journal:  Ophthalmic Genet       Date:  1997-12       Impact factor: 1.803

7.  Management of focal limbal stem cell deficiency associated with soft contact lens wear.

Authors:  Bennie H Jeng; Colleen P Halfpenny; David M Meisler; E Lee Stock
Journal:  Cornea       Date:  2011-01       Impact factor: 2.651

8.  Ocular manifestations in a father and son with EEC syndrome.

Authors:  B Käsmann; K W Ruprecht
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-08       Impact factor: 3.117

9.  Keratopathy in a family with the ectrodactyly-ectodermal dysplasia-clefting syndrome.

Authors:  L G Mawhorter; M S Ruttum; S B Koenig
Journal:  Ophthalmology       Date:  1985-10       Impact factor: 12.079

10.  Absent meibomian glands in the ectrodactyly, ectodermal dysplasia, cleft lip-palate syndrome.

Authors:  B J Mondino; P E Bath; R Y Foos; L Apt; G M Rajacich
Journal:  Am J Ophthalmol       Date:  1984-04       Impact factor: 5.258

View more
  8 in total

Review 1.  Nanotechnology in corneal neovascularization therapy--a review.

Authors:  Lilian Gonzalez; Raymond J Loza; Kyu-Yeon Han; Suhair Sunoqrot; Christy Cunningham; Patryk Purta; James Drake; Sandeep Jain; Seungpyo Hong; Jin-Hong Chang
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-20       Impact factor: 2.671

2.  Clinical features, surgical outcomes and genetic analysis of ectodermal dysplasia with ocular diseases.

Authors:  Xi Chen; Wei-Xuan Zeng; Bao-Ying Duan; Yan-Yan Lin; Jia Liu; Zong-Duan Zhang
Journal:  Int J Ophthalmol       Date:  2022-07-18       Impact factor: 1.645

3.  Preliminary report on screening IGSF3 gene mutation in families with congenital absence of lacrimal puncta and canaliculi.

Authors:  Fei Wang; Hai Tao; Cui Han; Fang Bai; Peng Wang; Xi-Bin Zhou; Li-Hua Wang; Chuan Liu
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

Review 4.  Limbal Stem Cell Deficiency: Current Treatment Options and Emerging Therapies.

Authors:  Michel Haagdorens; Sara Ilse Van Acker; Veerle Van Gerwen; Sorcha Ní Dhubhghaill; Carina Koppen; Marie-José Tassignon; Nadia Zakaria
Journal:  Stem Cells Int       Date:  2015-12-14       Impact factor: 5.443

5.  Potential Risks of Corneal Refractive Surgery in Patients with Ectodermal Dysplasia.

Authors:  Majid Moshirfar; Duncan J Williams; Yasmyne C Ronquillo; Briana K Ply
Journal:  Ophthalmol Ther       Date:  2022-05-09

6.  Ectodermal dysplasias: New perspectives on the treatment of so far immedicable genetic disorders.

Authors:  Holm Schneider
Journal:  Front Genet       Date:  2022-09-06       Impact factor: 4.772

Review 7.  Presentation, diagnosis and management of limbal stem cell deficiency.

Authors:  Kunjal Sejpal; Pejman Bakhtiari; Sophie X Deng
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Jan-Mar

8.  Allele-specific silencing of EEC p63 mutant R304W restores p63 transcriptional activity.

Authors:  F Novelli; A M Lena; E Panatta; W Nasser; R Shalom-Feuerstein; E Candi; G Melino
Journal:  Cell Death Dis       Date:  2016-05-19       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.